Mantle Cell Lymphoma Insights

A recent study led by Luan et al. (2025) has shown significant improvements in survival rates for older patients with mantle cell lymphoma (MCL). The study analysed data from over 5,400 patients diagnosed between 2002 and 2019 and found that advances in treatment, particularly the increased use of bendamustine-rituximab (BR) in first-line therapy and BTK inhibitors (BTKi) in second-line therapy, have contributed to better outcomes. The findings suggest that these newer therapies have played a crucial role in extending the time before patients need further treatment and improving overall survival.

These findings offer hope to individuals living with MCL, particularly older patients who may not be eligible for intensive treatments like stem cell transplants. The study highlights the importance of ongoing research into new therapies, as further advancements could continue to improve long-term survival and quality of life. If you or a loved one is managing MCL, discussing the latest treatment options with a healthcare provider could help determine the most effective approach based on individual health needs.